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ABSTRACT
Anti Retroviral Therapy has been started in Nepal since 2004 and the treatment centers have been upgrading all 
over the country regularly. A prospective observational study was carried out from August 2008 to December 
2009 with an objective to evaluate clinical outcome of People Living with HIV/AIDS undergoing the therapy 
as per National Guidelines. After taking written informed consent pre-structured questionnaire was fi lled 
and patients were followed for next six months. All information were entered into SPSS 11.5 system and 
analyzed. Out of 44 patients, 24 (54.6%) were males and 20 (45.4%) were females. Age group 31-35 years 
were predominant 16 (36.6%) followed by 36-40 years 12 (27.2%). Clinically WHO stage III was found among 
97.7% of the patients and 45.4% of housewives got HIV transmitted from husbands. Anti Retroviral Therapy 
was started in 25 (59.2%) of patients within three months HIV test positive. From initiation of therapy till six 
months there was, 1.7 kg of mean increase weight gain and 354 cells/mm3 increase in mean Total Lymphocyte 
Count. Opportunistic infections occurrence decreased signifi cantly from 34.1% to 2.3% and 41 (93.2%) patients 
had drug adherence scale of more than 95 percentile. Hence it can be concluded that there is an urgent need of 
expanding the accessibility of the therapy to eligible patients throughout the country.
Keywords: People living with HIV/AIDS, Anti Retroviral Therapy, Opportunistic Infections, drug adherence, 
Nepal
HIV infections by age groups: children (0-14 years): 
2.6%, adults (15-49 years): 93.2%, adults (above 50 
years): 4.7%. HIV infection occurs through three 
primary modes: sexual, parenteral and perinatal. Sexual 
intercourse is the most common method for transmission 
in Nepal.4,5
Anti Retroviral Therapy (ART) has been started in 
Nepal since February 2004 from Sukra Raj Tropical 
and Infectious Disease Control Hospital, Kathmandu. 
Until 2009, 23 centers have been upgraded throughout 
the country, total of 3,423 PLHA have been benefi ted by 
the therapy and estimated that 17,000 people are in need 
of therapy.6 ART has improved the health and survival 
prospects of PLHA and has transformed the fatal disease 
into chronic condition.7,8
The study is conducted with an objective to fi ne changes 
in the weight, occurrence of Opportunistic Infections, 
changes of laboratory parameters and drug adherence 
level of patient taking ART at rural general hospital 
were CD 4 cell count facility is absent. Furthermore this 
study is intended to draw the attention of policy makers, 
health administrators, health personnel and care givers 
about the health status of PLHA residing in rural part 
of the country.
INTRODUCTION
AIDS (Acquired Immunodeficiency Syndrome) 
caused by Human Immunodefi ciency virus (HIV) was 
recognized by medical community as a distinct clinical 
entity in 1981. The fi rst case of AIDS in India was 
reported in 1986. In Nepal fi rst HIV positive case was 
identifi ed in July 1988. The disease poses a signifi cant 
challenge to modern medicine and humanity. The burden 
of HIV/AIDS can be categorized as clinical, fi nancial, 
psychological and social. It can also be classifi ed as 
burden to patient, family, community and country.1
South East Asia has the second highest burden of HIV 
in the world where 4.1 million People living with 
HIV/AIDS (PLHA).2 In Nepal estimated number of 
HIV infection is 69,970 of which adult population 
infected is 64,585 but the reported HIV positives are 
14,747, including 2,627 PLHA. Though prevalence of 
HIV/AIDS is 0.5, epidemic has evolved from low to 
concentrated among high risk groups such as clients with 
sex workers (47.0%), housewives (20.0%), intravenous 
drug users (20.0%) and sex workers (7.0%). Report 
shows that the number of infected housewives is about 
three times higher than the number of sex workers.3 
Estimated number of
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MATERIALS AND METHODS
Prospective observational study was carried out at ART 
clinic of United Mission Hospital, Palpa between August 
2008 and December 2009. The research was approved 
by Institutional Review Board, Institute of Medicine, 
Tribhuvan University and Internal Management 
Committee of United Mission Hospital. After taking 
written informed consent, patients were interviewed to 
fi ll up the pre-structured questionnaire and the records 
were kept confi dential in the ART clinic and regularly 
fi lled on follow-up visits as per study protocol.
Total of 44 participates were included in the study. 
Inclusion criteria for the selection of patients were adults 
above the age of 18 years, new patients starting ART 
from the hospital clinic or within two weeks of start 
of ART transfer in to our center, WHO clinical staging 
III or IV without CD4 cell count and patients willing 
to follow up on monthly interval for next six months 
period. Any patients not matching above criteria were 
excluded from the study.
All the information were entered into SPSS system 
(statistical package for social sciences) and analyzed. 
The descriptive statistics such as frequency, percentage, 
mean, standard deviation, z-test and chi-square test were 
used according to the nature of the variables.
RESULTS
Among 44 PLHA 24 (54.6%) were males and 20 
(45.4%) were females. The age group of 31-35 years 
was predominant (36.3%) followed by 36-40 (27.2%). 
Most of them were illiterate (56.8%), married (88.6%), 
migrant labor/farmer (56.8%). The main mode of HIV 
transmission was by sexual contact and male acquired 
HIV infection from sex workers and later transmitted to 
their wives as shown in Table-1.
Interval time period between HIV testing and starting 
of ART was found to be within fi rst three months 56.8% 
followed by 22.8% after six months duration [Fig.1]. 
The WHO clinical staging of PLHA at the start of ART 
was as high as 97.7% of them were in stage III is shown 
in Fig.2. Weight monitoring record of PLHA showed 
47.7 kg,
Table-1: Socio-demographic characteristics of 
studied subjects by gender.






25-30 4 (16.8) 5 (25) 9 (20.5)
31-35 7 (29.1) 9 (45) 16 (36.3)
36-40 6 (25) 6 (30) 12 (27.3)
>41 7 (29.1) - 7 (15.9)
Total 24 (100) 20 (100) 44 (100)
Marital Status
Married 23(95.8) 16 (80) 39 (88.6)
Widow 1 (4.2) 4 (20) 5 (11.4)
Total 24 (100) 20 (100) 44 (100)
Education
Illiterate 8 (33.3) 17 (85) 25 (56.8)
Primary 16 (66.7) 3 (15) 19 (43.2)
Total 24 (100) 20 (100) 44 (100)
Occupation
Migrant /Farmer 22 (91.6) 3 (15) 25 (56.8)
Driver 2 (8.4) - 2 (4.6)
Housewife - 17 (85) 17 (38.6)
Total 24 (100) 20 (100) 44 (100)
HIV Transmission
Sex Workers 24 (100) - 24 (54.6)
Partners - 20 (100) 20 (45.4)
Total 24 (100) 20 (100) 44 (100)








Weight 47.7 kg 48.5 kg 49.4 kg






Fig. 1: Time interval between HIV testing and start of therapy.
Fig. 2: WHO stage of PLHA at start of therapy.
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48.5 kg and 49.4 kg at beginning, three months and six 
months duration respectively during treatment period. 
Blood hemoglobin level and Total Lymphocyte Count 
(TLC) were 10.4 gm/dl and 1124.5 cells/mm3 at start of 
therapy after three months were 10.7 gm/dl and 1236.2 
cells/mm3 and after six months were 10.8 gm/dl and 
1478.9 cells/mm3 respectively as shown in Table-2.
The drug adherence scale of above 95 percentile was 
93.2% among PLHA in the study group as shown in 
Fig.3. Opportunistic infections occurrence reduced from 
15 to 1 patients which was statistically signifi cant at p 
value of <0.05 level of signifi cance as shown in Fig.4.
DISCUSSION
One of the most important fi ndings of this study is the 
opportunistic infections occurrence decreased from 
34.1% to 2.3% after six months of therapy. This change 
is statistically signifi cant at 0.05 p value of level of 
signifi cance. The reduction of opportunistic infection 
supported the adherence to ART and is also due to 
additional use of Co-Trimoxazole DS tablet prophylactic 
in all patients. The fi nding is consistent with study of 
Anglaret et al which shows the reduction of serious 
illness up to 43% by the Co-Trimoxazole therapy.9
Age group 31-35 years were predominant 16 (36.6%) 
followed by 36-40 years 12 (27.2%). The study shows 
that economically productive age group is the most 
vulnerable age group with high HIV prevalence rate. 
This fi nding is similar to the national estimate that 
seroprevalance of < 1 percent among the age group 15 
to 49; posing a threat to become the nation’s number 
one killer of that age group.4 Moreover, the current 
demonstration of the very economically productive age 
of many of those HIV infected and the further harm to 
these young lives through high rates of HIV infection 
requires attention from public health researchers
and strategists to better understand and reduce the 
transmission of HIV.3
The numbers of male patients were 54.6% than those to 
female 45.4%. These fi ndings are also in accordance with 
the fact that more Nepalese male population is diagnosed 
as HIV positive than female population and this may be 
due to their early treatment seeking behavior than their 
counterparts. The ratio is almost similar to Srilanka 
where HIV positive men to women are 1.4:1.1
Majority of patients were married and 54.6% of them 
suspected the mode of transmission from sex works 
having unprotected sex while working outside the 
country. All of the female were married and suspected to 
have transmitted the disease from their partners indicating 
that the transmission of HIV among rural women takes 
place predominantly within the institution of marriage.3 
Sexual contact is the most common mode of transmission 
of HIV/ AIDS in rural part of the country.
Regarding the interval duration of HIV diagnosis from 
the starting of the ART, in 56.8% of patient’s ART was 
started within three months of their HIV test positive. In 
rest of the patients in whom therapy was started within 
six months and more than six months durations were 
20.4% and 22.8% respectively. Study from India showed 
evaluating the clinical outcome of patients on Highly Active 
Anti Retroviral Therapy (HAART) for six month have 
demonstrated improved in health status.10 These fi ndings 
were in accordance with results that 97.7% when started 
the therapy were in WHO Stage III of the disease.
The result regarding weight gain showed that the mean 
body weight increased from 47.7 kg to 49.4 kg after 6 
months of therapy. Study with follow up for one year 
recorded mean body weight increased from 49.4 kg to 
54.4 kg and were statistically signifi cant at the 0.05 level 
of signifi cance.11
Fig 3: Drug adherence scale of ART.duration Fig. 4: Opportunistic infection numbers during therapy duration
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Majority of the patients’ hemoglobin was below 11 
gm% with mean hemoglobin of 10.4 gm% at the start 
of the therapy and increased to mean 10.7 gm% and 
to mean 11.8 gm% at 3 months and 6 months period 
respectively.
Information regarding TLC which is established as a 
surrogate marker for CD 4 cells count in conjunction 
with clinical data as criteria to initiate HAART by 
WHO.12 The mean TLC increased was 354.4 cells/mm3 
from 1124.5 cells/mm3 to 1478.9 cells/mm3 after six 
months of antiretroviral therapy. Studies in developing 
country, Martin et al on monitoring CD 4 cells count 
have shown improvement 112 cells/mm3 to 273 cell/ 
mm3 after one year of therapy.13-15
According to National Guidelines for ART, more than 
95 percentile of compliance is required for optimal viral 
suppression. The lesser degree of adherence is more often 
associated with virological failure. A consensus exits that 
in order to achieve an undetectable viral load and prevent 
the development of drug resistance, a person on HAART 
needs at least above 95 percentile of prescribed dose on 
time.6 Tiyou et al study showed the adherence higher than 
the developed country and income generating activities 
and social supports main emphasis for success of ART.16 In 
this study, we found that 93.2% of people living with HIV/
AIDS had above 95 percentile adherence scale based on 
self reported interview questionnaire method. In patients 
6.8% had adherence scale of below 95 percentile. The 
indings of the study were similar with other study.17,18
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